Effect of low dose atropine eye drops on eye-related changes at near focal distances in children and young adults

Phase 2

Completed

• Conditions: Progressive myopia; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12621000563864
• Lead Sponsor: Queensland University of Technology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-13
• Study Completion: 2024-03-09
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Healthy myopic children, adolescents, and young adults aged 6 to 25 years and with a myopic refractive error between -0.50 and -5.00 DS, and no greater than 1.00 D of astigmatism or anisometropia. Participants will currently be corrected with spectacles or contact lenses.

Exclusion Criteria

• Current or previous use of myopia control treatments (atropine, OrthoK, peripheral defocus soft contact lenses or spectacle lenses)
• Amblyopia or strabismus
• Stereopsis of 200 seconds of arc or greater
• Monocular amplitude of accommodation of less than 8 D
• Best corrected visual acuity (BCVA) poorer than 0.1 logMAR in both eyes, or greater than 1 line (0.1 logMAR) difference in VA between eyes
• History of ocular surgery
• History of significant ocular infection or injury
• Known allergy to atropine, tropicamide, or benzalkonium chloride (BAK)
• Known angle closure glaucoma, or temporal VH ratio <0.3:1 in either eye
• Intraocular pressure greater than 21 mmHg in either eye
• Current use of: anticholinergics, antiglaucoma medications, antimyasthenics, potassium drugs, carbachol/physostigmine/pilocarpine, no CNS depressants (such as antiemetics, phenothiazines, or barbiturates).
• History of Down's syndrome, spastic paralysis, or brain damage.

Study & Design

• Study Type: Interventional
• Study Design: Not specified